Literature DB >> 35648267

Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: A pragmatic multicentre, prospective, randomized, controlled study.

Edoardo Ferlazzo1,2, Giorgia Giussani3, Sara Gasparini1,2, Elisa Bianchi3, Vittoria Cianci2, Vincenzo Belcastro4, Roberto Cantello5, Gionata Strigaro5, Matilde Lazzari5, Amedeo Bianchi6, Martina Guadagni6, Silvia Pradella6, Angela La Neve7, Teresa Francavilla7, Nicola Pilolli7, Paola Banfi8, Francesco Turco8, Marta Piccioli9, Luigi Polidori9, Teresa Anna Cantisani10, Rossella Papetti10, Michela Cecconi10, Elisabetta Pupillo3, Emilio Davide Arippol3, Gabriele Enia3, Sabrina Neri1,2, Umberto Aguglia11,12, Ettore Beghi3.   

Abstract

PURPOSE: To establish whether a slow or a rapid withdrawal of antiepileptic monotherapy influences relapse rate in seizure-free adults with epilepsy and calculates compliance and differences in the severity of relapses, based on the occurrence of status epilepticus, seizure-related injuries, and death.
METHODS: This is a multicentre, prospective, randomized, open label, non-inferiority trial in people aged 16 + years who were seizure-free for more than 2 years. Patients were randomized to slow withdrawal (160 days) or rapid withdrawal (60 days) and were followed for 12 months. The primary outcome was the probability of a first seizure relapse within the 12-months follow-up. The secondary outcomes included the cumulative probability of relapse at 3, 6, 9, and 12 months. A non-inferiority analysis was performed with non-inferiority margin of - 0.15 for the difference between the probabilities of seizure recurrence in slow versus rapid withdrawal.
RESULTS: The sample comprised 48 patients, 25 randomized to slow withdrawal and 23 to rapid withdrawal. Median follow-up was 11.9 months. In the intention-to-treat population, 3 patients in the slow-withdrawal group and 1 in the rapid withdrawal group experienced seizure relapses. The corresponding probabilities of seizure recurrence were 0.12 for slow withdrawal and 0.04 for rapid withdrawal, giving a difference of 0.08 (95% CI - 0.12; 0.27), which is entirely above the non-inferiority margin. No patients developed status epilepticus and seizure-related injuries or died. Risks were similar in the Per-Protocol population.
CONCLUSIONS: Seizure-relapse rate after drug discontinuation is lower than in other reports, without complications and unrelated to the duration of tapering.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Antiseizure medication; Drug withdrawal; Seizure freedom; Seizure relapse; Tapering

Mesh:

Substances:

Year:  2022        PMID: 35648267     DOI: 10.1007/s10072-022-06121-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  12 in total

1.  Prognosis after therapy discontinuation in children with epilepsy.

Authors:  C Mastropaolo; M Tondi; F Carboni; S Manca; F Zoroddu
Journal:  Eur Neurol       Date:  1992       Impact factor: 1.710

2.  Early identification of refractory epilepsy.

Authors:  P Kwan; M J Brodie
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

Review 3.  Withdrawal of antiepileptic drugs: guidelines of the Italian League Against Epilepsy.

Authors:  Ettore Beghi; Giorgia Giussani; Salvatore Grosso; Alfonso Iudice; Angela La Neve; Francesco Pisani; Luigi M Specchio; Alberto Verrotti; Giuseppe Capovilla; Roberto Michelucci; Gaetano Zaccara
Journal:  Epilepsia       Date:  2013-10       Impact factor: 5.864

4.  Relapse following discontinuation of antiepileptic drugs: a meta-analysis.

Authors:  A T Berg; S Shinnar
Journal:  Neurology       Date:  1994-04       Impact factor: 9.910

5.  Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study).

Authors:  Morten Ingvar Lossius; Erik Hessen; Petter Mowinckel; Knut Stavem; Jan Erikssen; Paal Gulbrandsen; Leif Gjerstad
Journal:  Epilepsia       Date:  2007-09-19       Impact factor: 5.864

Review 6.  Should antiepileptic drugs be withdrawn in seizure-free patients?

Authors:  Luigi M Specchio; Ettore Beghi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study.

Authors:  Sara Gasparini; Edoardo Ferlazzo; Giorgia Giussani; Domenico Italiano; Vittoria Cianci; Chiara Sueri; Edoardo Spina; Ettore Beghi; Umberto Aguglia
Journal:  Neurol Sci       Date:  2016-01-25       Impact factor: 3.307

8.  Rates of antiepileptic drug reduction in active epilepsy--current practice.

Authors:  J S Duncan; S D Shorvon
Journal:  Epilepsy Res       Date:  1987 Nov-Dec       Impact factor: 3.045

Review 9.  The natural history and prognosis of epilepsy.

Authors:  Ettore Beghi; Giorgia Giussani; Josemir W Sander
Journal:  Epileptic Disord       Date:  2015-09       Impact factor: 1.819

10.  Stopping medication in children with epilepsy: predictors of outcome.

Authors:  R Emerson; B J D'Souza; E P Vining; K R Holden; E D Mellits; J M Freeman
Journal:  N Engl J Med       Date:  1981-05-07       Impact factor: 91.245

View more
  1 in total

1.  Late seizures following cerebral venous thrombosis-may be a maladaptive attempt to release gravitational ischemia in the brain.

Authors:  J Howard Jaster; Giulia Ottaviani
Journal:  Neurol Sci       Date:  2022-07-11       Impact factor: 3.830

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.